Mind Medicine (MMQ) Price & Analysis

Compare

11 Followers

MMQ Stock Chart & Stats

€10.45

-€0.45(-5.84%)

At close: Jan 08 4:00 PM EST

€10.45

-€0.45(-5.84%)

Day’s Range― - ―

52-Week Range€4.29 - €12.21

Previous CloseN/A

Volume187.00

Average Volume (3M)254.00

Market Cap

$1.05B

Enterprise Value€843.91M

Total Cash (Recent Filing)$209.07M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.37

Next Earnings

Mar 05, 2026

EPS Estimate

-0.44

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.66

Shares Outstanding98,509,280

10 Day Avg. Volume170

30 Day Avg. Volume254

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)2.03

Price to Sales (P/S)0.00

P/FCF Ratio-6.20

Enterprise Value/Market Cap0.80

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-5.17

Forecast

1Y Price Target

$24.30

Price Target Upside132.56% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial StrengthMindMed secured $259M in financing, ensuring funding into 2028, which supports the completion of key programs.

Market PotentialMNMD remains significantly undervalued as key Phase 3 data readouts for generalized anxiety disorder and major depressive disorder present great unmet need and significant market opportunity.

Regulatory ProgressContinued interactions with FDA further support alignment with the rigor and design of the pivotal programs and low turnover in the psychiatric department, de-risk the trials and path to approval.

Bears Say

Mind Medicine News

Psychedelic: Atai Beckley, Cybin report quarterly earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

29d ago

PBM

ABBV

MindMed’s Earnings Call: Positive Outlook Amid Financial Challenges

Mind Medicine Inc. (($MNMD)) has held its Q3 earnings call. Read on for the main highlights of the...

1M ago

MNMD

Mind Medicine’s Strong Financial Position and Clinical Progress Drive Buy Rating

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on MNMD stock, giving a Buy rating today....

1M ago

MNMD

Mind Medicine’s Promising Clinical Progress and Strategic Advancements Justify Buy Rating

Analyst Francois Brisebois of LifeSci Capital reiterated a Buy rating on Mind Medicine, retaining the price target of...

1M ago

MNMD

Mind Medicine price target raised to $25 from $16 at Canaccord

Canaccord raised the firm’s price target on Mind Medicine (MNMD) to $25 from $16 and keeps a Buy...

1M ago

MNMD

Mind Medicine’s Accelerated Phase 3 Trials and Strong Financial Position Signal Promising Future

Analyst Ami Fadia from Needham reiterated a Buy rating on Mind Medicine and keeping the price target at...

1M ago

MNMD

MindMed Reports Q3 2025 Financial Progress

Mind Medicine Inc. ( ($MNMD) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

MNMD

Mind Medicine Reports Q3 2025 Financial Results

An announcement from Mind Medicine ( ($MNMD) ) is now available. MindMed reported its Q3 2025 financial results...

1M ago

MNMD

Mind Medicine reports Q3 EPS (78c), consensus (50c)

“2025 continues to be a year of strong execution, and our recent $258.9 million financing further strengthens our...

1M ago

MNMD

MindMed Secures $259 Million in Public Offering to Advance Brain Health Innovations

Mind Medicine ( ($MNMD) ) has shared an update. Mind Medicine (MindMed) Inc. announced the successful closing of...

1M ago

MNMD

MindMed Issues Inducement Grants to New Employees

The latest update is out from Mind Medicine ( ($MNMD) ). MindMed announced the issuance of inducement grants...

1M ago

MNMD

Mind Medicine Completes Successful Public Offering

The latest announcement is out from Mind Medicine ( ($MNMD) ). On October 29, 2025, MindMed entered into...

1M ago

MNMD

Mind Medicine 18.375M share Spot Secondary priced at $12.25

Jefferies, Leerink and Evercore ISI acted as joint book running managers for the offering. Published first on TheFly...

1M ago

MNMD

MindMed Highlights Strategic Focus in New Presentation

An announcement from Mind Medicine ( ($MNMD) ) is now available. On October 29, 2025, MindMed released a...

1M ago

MNMD

MMQ FAQ

What was Mind Medicine’s price range in the past 12 months?

Mind Medicine lowest stock price was €4.29 and its highest was €12.21 in the past 12 months.

What is Mind Medicine’s market cap?

Mind Medicine’s market cap is $1.05B.

When is Mind Medicine’s upcoming earnings report date?

Mind Medicine’s upcoming earnings report date is Mar 05, 2026 which is in 83 days.

How were Mind Medicine’s earnings last quarter?

Mind Medicine released its earnings results on Nov 06, 2025. The company reported -€0.665 earnings per share for the quarter, missing the consensus estimate of -€0.427 by -€0.238.

Is Mind Medicine overvalued?

According to Wall Street analysts Mind Medicine’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mind Medicine pay dividends?

Mind Medicine does not currently pay dividends.

What is Mind Medicine’s EPS estimate?

Mind Medicine’s EPS estimate is -0.44.

How many shares outstanding does Mind Medicine have?

Mind Medicine has 98,509,280 shares outstanding.

What happened to Mind Medicine’s price movement after its last earnings report?

Mind Medicine reported an EPS of -€0.665 in its last earnings report, missing expectations of -€0.427. Following the earnings report the stock price went up 1.143%.

Which hedge fund is a major shareholder of Mind Medicine?

Currently, no hedge funds are holding shares in DE:MMQ

Mind Medicine Stock Smart Score

Outperform

Fundamentals

Return on Equity

-85.59%

Trailing 12-Months

Asset Growth

-25.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mind Medicine

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Mind Medicine (MMQ) Earnings & Revenues

Historic Earnings Reports

MMQ Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflects a largely positive outlook for Mind Medicine (MindMed) Inc., with significant achievements in clinical trial progress, financial strengthening through capital raise, and promising advancements in their pipeline. However, increased expenses and net loss reflect some financial challenges.View all DE:MMQ earnings summaries

MMQ Stock 12 Month Forecast

Average Price Target

€24.30

▲(132.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","15":"€15","26":"€26","37":"€37","48":"€48"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47.3148401,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€47.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.302622415,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.48485676,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€15.48</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,15,26,37,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.04,14.753449238461538,17.466898476923078,20.180347715384613,22.893796953846152,25.60724619230769,28.320695430769227,31.034144669230766,33.747593907692305,36.46104314615384,39.174492384615384,41.88794162307692,44.601390861538455,{"y":47.3148401,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.04,12.983278647307692,13.926557294615383,14.869835941923077,15.813114589230768,16.75639323653846,17.699671883846154,18.642950531153843,19.586229178461537,20.52950782576923,21.472786473076923,22.416065120384616,23.35934376769231,{"y":24.302622415,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.04,12.304988981538461,12.569977963076923,12.834966944615385,13.099955926153845,13.364944907692307,13.629933889230768,13.89492287076923,14.159911852307692,14.424900833846152,14.689889815384614,14.954878796923076,15.219867778461538,{"y":15.48485676,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.935,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.505,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.89,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.475,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >